Company Overview

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing protein replacement therapies for rare genetic diseases. The company operates within the biotechnology and life sciences industry, with a primary emphasis on neurological and neuromuscular disorders. Larimar’s core mission is to address diseases caused by deficiencies in mitochondrial or intracellular proteins that are not adequately treated by existing therapies.

The company’s principal product candidate is CTI-1601 (nomlabofusp), a recombinant human frataxin protein conjugated to a cell-penetrating peptide, being developed for the treatment of Friedreich’s ataxia, a rare, inherited neurodegenerative disease. Larimar’s strategic positioning centers on its proprietary intracellular delivery platform designed to enable systemic protein replacement, which differentiates it from gene therapy and small-molecule approaches. The company was originally founded as Tisone Therapeutics and rebranded as Larimar Therapeutics, Inc. in 2018 following a strategic refocus on rare disease protein therapeutics.

Business Operations

Larimar operates as a single-reportable-segment biotechnology company, with substantially all activities focused on research and development. Revenue generation is currently limited, as the company does not have any approved commercial products and relies primarily on capital raised through equity offerings to fund operations. Core activities include preclinical research, clinical trial execution, regulatory engagement, and manufacturing development for its therapeutic candidates.

Operations are primarily conducted in the United States, with clinical trials managed through a combination of internal teams and third-party contract research organizations. Larimar controls proprietary technology related to protein engineering and intracellular delivery and holds intellectual property covering its lead therapeutic candidate. The company does not report any material operating subsidiaries or joint ventures, and it relies on external manufacturing partners for clinical-grade drug substance and drug product.

Strategic Position & Investments

Larimar’s strategic direction is centered on advancing CTI-1601 (nomlabofusp) through clinical development toward potential regulatory approval for Friedreich’s ataxia. Growth initiatives focus on completing ongoing clinical trials, optimizing dosing and delivery, and engaging with regulatory authorities to define approval pathways. The company also evaluates lifecycle management opportunities and potential expansion of its platform to additional rare diseases with similar biological mechanisms.

Investment activity is primarily directed toward internal research and development rather than external acquisitions. To date, Larimar has not completed significant mergers or acquisitions and does not maintain a diversified portfolio of subsidiaries. Its emerging technology focus remains on intracellular protein replacement, a niche area within rare disease therapeutics that may offer advantages in controllability and safety relative to gene-based approaches.

Geographic Footprint

Larimar Therapeutics is headquartered in Bala Cynwyd, Pennsylvania, and its operational footprint is predominantly based in the United States. Corporate management, research oversight, and regulatory strategy are centrally coordinated from its U.S. headquarters.

While the company does not maintain significant physical operations outside the United States, its clinical development programs have included trial sites in North America, and it engages with international regulatory bodies as part of long-term planning. Larimar’s global presence is primarily indirect, achieved through clinical collaborations, contract manufacturers, and service providers supporting international aspects of drug development.

Leadership & Governance

Larimar is led by an experienced management team with backgrounds in biotechnology, clinical development, and finance. The leadership’s strategic vision emphasizes disciplined clinical execution, patient-focused development in rare diseases, and long-term value creation through innovative protein therapeutics. Corporate governance follows U.S. public company standards and is overseen by an independent board of directors.

Key executives include:

• Carole Ben-Maimon, MD – President & Chief Executive Officer
• Richard A. Blumberg – Executive Vice President & Chief Financial Officer
• Susan Perlman, MD – Chief Medical Officer

The leadership team’s philosophy centers on scientific rigor, regulatory alignment, and close engagement with patient communities affected by rare genetic disorders.